ClinicalTrials.gg
CompletedNCT02725567Updated Sep 7, 2023Results posted

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

A Phase 3 interventional study of IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 23 sites in 5 countries. Open to participants aged 1 Month to 24 Months. Per ClinicalTrials.gov, last updated 2023-09-07.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
1 Month to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.

Enrollment
49th of 84
57 · median 70
Started
2016
with 9 others
Phase 3
45 of 84
none open now
Registered
38th of 84
by date
Lead sponsor
74 of 84
Vertex Pharmaceuticals Incorporated

Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 49th largest by enrollment, is one of 10 that started in 2016, is one of 45 in phase 3, and was the 38th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ivacaftor

ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 1 Month to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing ivacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in participants with cystic fibrosis (CF) who are \<24 months of age at treatment initiation and have an ivacaftor-responsive CF transmembrane conductance regulator (CFTR) gene mutation.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
1 Month to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CF by sweat chloride value or CF mutation criteria.
  • Have 1 of the following 10 CFTR mutations on at least 1 allele: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, G1349D or R117H (eligible in regions where ivacaftor is approved for use). Part A/B group may also have other ivacaftor-responsive mutations.
  • Hematology, serum chemistry, and vital signs results at screening with no abnormalities that would interfere with the study assessments, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant
  • Colonization with organisms associated with a more rapid decline in pulmonary status at screening (Only for Parts A and B)
  • History of abnormal liver function or abnormal liver function at screening
  • History of solid organ or hematological transplantation
  • Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A within 2 weeks before Day 1
  • Participation in a clinical study involving administration of either an or a marketed drug within 30 days or 5 terminal half-lives before screening
  • (Hgb) \<9.5 g/dL at screening
  • Chronic kidney disease of Stage 3 or above
  • Presence of a non-congenital or progressive lens opacity or cataract at Screening

Other protocol defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Part A: 3 to <24 months

    Participants weighing 5 to less than (\<) 7 kilogram (kg) received 25 milligram (mg) IVA, 7 to \<14 kg received 50 mg IVA, and those weighing 14 to \<25 kg received 75 mg IVA administered every 12 hours (q12h) on Days 1 through 3 and 1 morning dose on Day 4.

    Drug: IVA

  • Experimental
    Part B + A/B:1 to < 24 months

    Participants 4 to \<6 months of age and weighing greater than or equal to (≥) 5 kg received 25 mg IVA q12h. At 6 months of age and older, participants weighing 5 to \<7 kg received 25 mg IVA, 7 to \<14 kg received 50 mg IVA, and those weighing 14 to \<25 kg received 75 mg IVA q12h for 24 weeks on Part B. For Part A/B, participants 1 to \<4 months weighing 3 kg to \<5 kg received an initial low dose of 5.7 mg q12h IVA and those weighing ≥5 kg received 11.4 mg q12h IVA for the first 15 days of IVA treatment. Doses were maintained or adjusted upward at Day 15 and based on weight and/or age once they reached 4 months of age.

    Drug: IVA

Interventions

  • DrugIVA

    Granules in sachet for oral administration.

    Also known as: VX-770, ivacaftor

06

What researchers measure

Primary outcomes

  1. Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious (TEAEs)

    Time frame: Day 1 through Day 70

  2. Part A: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA)

    Time frame: Pre-dose, 2-4 hours, 6-8 hours, 24-60 hours post-dose

  3. Part B +A/B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious (TEAEs)

    Time frame: Day 1 through Week 38

  4. Part A/B: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA)

    Time frame: Day 4 (pre-dose, 2-4 hours, 6-8 hours post-dose); Day 15 (pre-dose); Week 4 (pre-dose); Week 8 (pre-dose, 2-4 hours, 6-8 hours post-dose); Week 12 (pre-dose); Week 18 (pre-dose) and Week 24 (pre-dose)

Secondary outcomes

  1. Part B: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA)

    Time frame: Week 2 (pre-dose, 2-4 hours, 6-8 hours post-dose); Week 8 (pre-dose,1 hour, 4-hour post-dose); Week 24 (pre-dose, 2-4 hours post dose)

  2. Part B + A/B: Absolute Change From Baseline in Sweat Chloride

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline at Week 24

07

Results

Posted Sep 7, 2023

Participant flow

This study was conducted in participants with cystic fibrosis (CF) who were less than (\<) 24 months of age at Day 1 and have an ivacaftor-responsive CF transmembrane conductance regulator (CFTR) mutation.

Part A (Up to 5 Days)
Participant flow — Part A (Up to 5 Days)
MilestonePart A: 3 to < 24 MonthsPart B + A/B: 1 to < 24 Months
Started190
Completed190
Not completed00
Part B + A/B ( Up to 24 Weeks)
Participant flow — Part B + A/B ( Up to 24 Weeks)
MilestonePart A: 3 to < 24 MonthsPart B + A/B: 1 to < 24 Months
Started043
Completed040
Not completed03
Withdrew: Lost to follow-up01
Withdrew: Physician decision01
Withdrew: Withdrawal of consent (not due to adverse event)01

Outcome measures

PrimaryPart A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious (TEAEs)
Time frame:
Day 1 through Day 70
Reported as:
Count of participants · Participants
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious (TEAEs)
ParticipantsPart A: 3 to < 24 Months
Participants with TEAEs10
Participants with Serious TEAEs1
PrimaryPart A: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA)
Time frame:
Pre-dose, 2-4 hours, 6-8 hours, 24-60 hours post-dose
Reported as:
Mean · nanogram per milliliter (ng/ml)
Part A: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA)
nanogram per milliliter (ng/ml)Part A: 3 to < 24 Months
Pre dose: IVA654 ± 531
Pre dose: M1-IVA1880 ± 1160
Pre dose: M6-IVA2680 ± 1990
2-4 hrs post dose: IVA956 ± 497
2-4 hrs post dose: M1-IVA1990 ± 1160
2-4 hrs post dose: M6-IVA2460 ± 2110
6-8 hrs post dose: IVA1040 ± 623
6-8 hrs post dose: M1-IVA2440 ± 1260
6-8 hrs post dose: M6-IVA2880 ± 2180
24-60 hrs post dose: IVA129 ± 68.8
24-60 hrs post dose: M1-IVA508 ± 228
24-60 hrs post dose: M6-IVA1100 ± 982
PrimaryPart B +A/B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious (TEAEs)
Time frame:
Day 1 through Week 38
Reported as:
Count of participants · Participants
Part B +A/B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious (TEAEs)
ParticipantsPart B + A/B: 1 to <24 Months
Participants with TEAEs38
Participants with Serious (TEAEs)6
PrimaryPart A/B: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA)
Time frame:
Day 4 (pre-dose, 2-4 hours, 6-8 hours post-dose); Day 15 (pre-dose); Week 4 (pre-dose); Week 8 (pre-dose, 2-4 hours, 6-8 hours post-dose); Week 12 (pre-dose); Week 18 (pre-dose) and Week 24 (pre-dose)
Reported as:
Mean · ng/ml
Part A/B: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA)
ng/mlPart A/B: 1 to <4 Months
Day 4 (pre dose): IVA348 ± 151
Day 4 (pre dose): M1-IVA867 ± 412
Day 4 (pre dose): M6-IVA1570 ± 570
Day 4 (2-4 hrs post dose): IVA381 ± 135
Day 4 (2-4 hrs post dose): M1-IVA851 ± 333
Day 4 (2-4 hrs post dose): M6-IVA1370 ± 450
Day 4 (6-8 hrs post dose): IVA501 ± 196
Day 4 (6-8 hrs post dose): M1-IVA1190 ± 420
Day 4 (6-8 hrs post dose): M6-IVA1670 ± 551
Day 15 (pre dose): IVA191 ± 134
Day 15 (pre dose): M1-IVA614 ± 378
Day 15 (pre dose): M6-IVA1510 ± 1110
Week 4 (pre dose): IVA316 ± 130
Week 4 (pre dose): M1-IVA1170 ± 577
Week 4 (pre dose): M6-IVA3370 ± 2330
Week 8 (pre dose): IVA449 ± 352
Week 8 (pre dose): M1-IVA1030 ± 476
Week 8 (pre dose): M6-IVA2380 ± 1500
Week 8 (2-4 hrs post dose): IVA523 ± 262
Week 8 (2-4 hrs post dose): M1-IVA1360 ± 982
Week 8 (2-4 hrs post dose): M6-IVA2100 ± 1540
Week 8 (6-8 hrs post dose): IVA438 ± 79.8
Week 8 (6-8 hrs post dose): M1-IVA1420 ± 606
Week 8 (6-8 hrs post dose): M6-IVA2320 ± 1330
Week 12 (pre dose): IVA213 ± 173
Week 12 (pre dose): M1-IVA906 ± 660
Week 12 (pre dose): M6-IVA2500 ± 1760
Week 18 (pre dose): IVA226 ± 153
Week 18 (pre dose): M1-IVA815 ± 470
Week 18 (pre dose): M6-IVA2060 ± 1190
Week 24 (pre dose): IVA276 ± 137
Week 24 (pre dose): M1-IVA1120 ± 496
Week 24 (pre dose): M6-IVA2380 ± 799
SecondaryPart B: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA)
Time frame:
Week 2 (pre-dose, 2-4 hours, 6-8 hours post-dose); Week 8 (pre-dose,1 hour, 4-hour post-dose); Week 24 (pre-dose, 2-4 hours post dose)
Reported as:
Mean · ng/ml
Part B: Observed Plasma Concentration of IVA and Their Metabolites (M1-IVA and M6-IVA)
ng/mlPart B: 4 to <24 Months
Week 2 (pre dose): IVA457 ± 441
Week 2 (pre dose): M1-IVA1340 ± 934
Week 2 (pre dose): M6-IVA1980 ± 1790
Week 2 (2-4 hrs post dose): IVA812 ± 726
Week 2 (2-4 hrs post dose): M1-IVA1560 ± 1190
Week 2 (2-4 hrs post dose): M6-IVA1770 ± 1970
Week 2 (6-8 hrs post dose): IVA969 ± 705
Week 2 (6-8 hrs post dose): M1-IVA2210 ± 1360
Week 2 (6-8 hrs post dose): M6-IVA2140 ± 1880
Week 8 (pre dose): IVA404 ± 376
Week 8 (pre dose): M1-IVA1220 ± 782
Week 8 (pre dose): M6-IVA1720 ± 1110
Week 8 (1 hrs post dose): IVA466 ± 384
Week 8 (1 hrs post dose): M1-IVA1100 ± 670
Week 8 (1 hrs post dose): M6-IVA1500 ± 881
Week 8 (4 hrs post dose): IVA996 ± 520
Week 8 (4 hrs post dose): M1-IVA2130 ± 950
Week 8 (4 hrs post dose): M6-IVA1750 ± 1010
Week 24 (pre dose): IVA301 ± 204
Week 24 (pre dose): M1-IVA1050 ± 492
Week 24 (pre dose): M6-IVA1600 ± 783
Week 24 (2-4 hrs post dose): IVA794 ± 480
Week 24 (2-4 hrs post dose): M1-IVA1540 ± 783
Week 24 (2-4 hrs post dose): M6-IVA1320 ± 592
SecondaryPart B + A/B: Absolute Change From Baseline in Sweat Chloride

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline at Week 24
Reported as:
Mean · millimole per liter (mmol/L)
Part B + A/B: Absolute Change From Baseline in Sweat Chloride
millimole per liter (mmol/L)Part B + A/B: 1 to < 24 Months
Part B + A/B: Absolute Change From Baseline in Sweat Chloride-62.0 ± 22.2

Adverse events

Collected over From Day 1 Through Safety Follow-up Period (up to Day 70 for Part A and up to Week 38 for Part B + A/B). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: 3 to < 24 Months0/19 (0%)1/19 (5.3%)10/19 (52.6%)
Part B + A/B: 1 to <24 Months0/43 (0%)6/43 (14%)34/43 (79.1%)
Most frequent serious events
Most frequent serious events
EventPart A: 3 to < 24 MonthsPart B + A/B: 1 to <24 Months
ThrombocytopeniaBlood and lymphatic system disorders1/190/43
CoughRespiratory, thoracic and mediastinal disorders0/192/43
ConstipationGastrointestinal disorders0/191/43
Distal intestinal obstruction syndromeGastrointestinal disorders0/191/43
BronchiolitisInfections and infestations0/191/43
Eczema CoxsackiumInfections and infestations0/191/43
Eczema herpeticumInfections and infestations0/191/43
Respiratory tract infection viralInfections and infestations0/191/43
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPart A: 3 to < 24 MonthsPart B + A/B: 1 to <24 Months
CoughRespiratory, thoracic and mediastinal disorders4/1924/43
PyrexiaGeneral disorders0/1912/43
RhinorrhoeaRespiratory, thoracic and mediastinal disorders1/1912/43
VomitingGastrointestinal disorders1/198/43
Alanine aminotransferase increasedInvestigations0/198/43
Upper respiratory tract infectionInfections and infestations1/197/43
Aspartate aminotransferase increasedInvestigations0/197/43
ConstipationGastrointestinal disorders1/196/43
Otitis mediaInfections and infestations0/196/43
Nasal congestionRespiratory, thoracic and mediastinal disorders1/196/43

Baseline characteristics

All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis.

Age, Customized
Age, Customized(Participants)Ivacaftor (IVA)
Part A — 12 to <24 months7
Part A — 6 to <12 months6
Part A — 4 to <6 months4
Part A — 1 to <4 months2
Part B+ A/B — 12 to <24 months19
Part B+ A/B — 6 to <12 months11
Part B+ A/B — 4 to <6 months6
Part B+ A/B — 1 to <4 months7
Sex: Female, Male
Sex: Female, Male(Participants)Ivacaftor (IVA)
Part A — Female10
Part A — Male9
Part B + A/B — Female22
Part B + A/B — Male21
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ivacaftor (IVA)
Part A — Hispanic or Latino0
Part A — Not Hispanic or Latino19
Part A — Not collected per local regulations0
Part B + A/B — Hispanic or Latino1
Part B + A/B — Not Hispanic or Latino42
Part B + A/B — Not collected per local regulations0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ivacaftor (IVA)
Part A — White19
Part A — Black or African American0
Part A — Asian0
Part A — American Indian or Alaska Native0
Part A — Native Hawaiian or Other Pacific Islander0
Part A — Not collected per local Regulations0
Part B + A/B — White43
Part B + A/B — Black or African American0
Part B + A/B — Asian0
Part B + A/B — American Indian or Alaska Native0
Part B + A/B — Native Hawaiian or Other Pacific Islander0
Part B + A/B — Not collected per local Regulations0
08

Study locations

23 sites
  • Birmingham, Alabama, United States
  • Palo Alto, California, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Indianapolis, Indiana, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Kansas City, Missouri, United States
  • Columbus, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Houston, Texas, United States
  • Seattle, Washington, United States
  • Madison, Wisconsin, United States
  • Parkville, Victoria, Australia
  • South Brisbane, Australia
  • Westmead, Australia
  • Toronto, Canada
  • Dublin, Ireland
  • Edinburgh, United Kingdom
  • Leicester, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
  • Oxford, United Kingdom
09

References and documents

Publications

  • Davies JC, Wainwright CE, Sawicki GS, Higgins MN, Campbell D, Harris C, Panorchan P, Haseltine E, Tian S, Rosenfeld M. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021 Mar 1;203(5):585-593. doi: 10.1164/rccm.202008-3177OC. PubMed 33023304 ↗
  • Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, Tian S, Schneider J, Cunningham S, Davies JC; ARRIVAL study group. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med. 2018 Jul;6(7):545-553. doi: 10.1016/S2213-2600(18)30202-9. Epub 2018 Jun 7. Erratum In: Lancet Respir Med. 2018 Jul;6(7):e35. doi: 10.1016/S2213-2600(18)30244-3. Lancet Respir Med. 2019 Apr;7(4):e15. doi: 10.1016/S2213-2600(19)30094-3. PubMed 29886024 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Jun 2022, 72 months.

Results were first posted in Sep 2023, 1 year 2 months after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 72 months is above that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2016
First posted
Apr 1, 2016
StartActual
Jun 2, 2016
Primary completionActual
Jun 28, 2022
CompletionActual
Jun 28, 2022
Results first posted
Sep 7, 2023
Last update
Sep 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02725567
Responsible party
Sponsor
First posted
Apr 1, 2016
Start date
Jun 2, 2016
Primary completion
Jun 28, 2022
Completion
Jun 28, 2022
Results posted
Sep 7, 2023
Last update
Sep 7, 2023

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivacaftor

Start the discussion